References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2021-4703

russjcardiol-4703

Research Article

ЗАКЛЮЧЕНИЕ СОВЕТА ЭКСПЕРТОВ

EXPERT COUNCIL OPINION

Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии

Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy

Васюк

Ю. А.

Vasyuk

Yu. A.

yvasyuk@yandex.ru

Гендлин

Г. Е.

Gendlin

G. E.

Емелина

Е. И.

Emelina

E. I.

Шупенина

Е. Ю.

Shupenina

E. Yu.

Баллюзек

М. Ф.

Ballyuzek

M. F.

Баринова

И. В.

Barinova

I. V.

Виценя

М. В.

Vitsenya

M. V.

Давыдкин

И. Л.

Davydkin

I. L.

Дундуа

Д. П.

Dundua

D. P.

Дупляков

Д. В.

Duplyakov

D. V.

Затейщиков

Д. А.

Zateishchikov

D. A.

Золотовская

И. А.

Zolotovskaya

I. A.

Конради

А. О.

Konradi

A. O.

Лопатин

Ю. М.

Lopatin

Yu. M.

Моисеева

О. М.

Moiseeva

O. M.

Недогода

С. В.

Nedogoda

S. V.

Недошивин

А. О.

Nedoshivin

A. O.

Никитин

И. Г.

Nikitin

I. G.

Полтавская

М. Г.

Poltavskaya

M. G.

Потиевская

В. И.

Potievskaya

V. I.

Репин

А. Н.

Repin

A. N.

Сумин

А. Н.

Sumin

А. N.

Зотова

Г. А.

Zotova

L. A.

Тумян

Г. С.

Tumyan

G. S.

Шляхто

Е. В.

Shlyakhto

E. V.

Хатьков

И. Е.

Khatkov

I. E.

Якушин

С. С.

Yakushin

S. S.

Беленков

Ю. Н.

Belenkov

Yu. N.

2021

27092021

26947034703

Copyright © Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В., Виценя М.В., Давыдкин И.Л., Дундуа Д.П., Дупляков Д.В., Затейщиков Д.А., Золотовская И.А., Конради А.О., Лопатин Ю.М., Моисеева О.М., Недогода С.В., Недошивин А.О., Никитин И.Г., Полтавская М.Г., Потиевская В.И., Репин А.Н., Сумин А.Н., Зотова Г.А., Тумян Г.С., Шляхто Е.В., Хатьков И.Е., Якушин С.С., Беленков Ю.Н., 2021

2021

Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В., Виценя М.В., Давыдкин И.Л., Дундуа Д.П., Дупляков Д.В., Затейщиков Д.А., Золотовская И.А., Конради А.О., Лопатин Ю.М., Моисеева О.М., Недогода С.В., Недошивин А.О., Никитин И.Г., Полтавская М.Г., Потиевская В.И., Репин А.Н., Сумин А.Н., Зотова Г.А., Тумян Г.С., Шляхто Е.В., Хатьков И.Е., Якушин С.С., Беленков Ю.Н.

Vasyuk Y.A., Gendlin G.E., Emelina E.I., Shupenina E.Y., Ballyuzek M.F., Barinova I.V., Vitsenya M.V., Davydkin I.L., Dundua D.P., Duplyakov D.V., Zateishchikov D.A., Zolotovskaya I.A., Konradi A.O., Lopatin Y.M., Moiseeva O.M., Nedogoda S.V., Nedoshivin A.O., Nikitin I.G., Poltavskaya M.G., Potievskaya V.I., Repin A.N., Sumin А.N., Zotova L.A., Tumyan G.S., Shlyakhto E.V., Khatkov I.E., Yakushin S.S., Belenkov Y.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4703

химиотерапиялучевая терапиятаргетная терапияпрофилактика кардиотоксичностилечение кардиотоксичности

chemotherapyradiation therapytargeted therapyprevention of cardiotoxicitytreatment of cardiotoxicity

References1

Eschenhagen T, Forse T, Ewer M, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011;13(1):1-10. doi:10.1093/eurjhf/hfq213.

Бедрицкий С.А., Ларионов В.Б., Снеговой А.В. Клинические рекомендации по кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Москва. 2014. с.1. http://www.oncology.ru/association/clinical-guidelines/2014/14.pdf.

Bedritsky SA, Larionova VB, Snegovoy AV. Clinical guidelines for cardiovascular toxicity induced by chemotherapy and targeted drugs. Moscow. 2014. р. 10. (In Russ.) http://www.oncology.ru/association/clinical-guidelines/2014/14.pdf.

Global WHO. Globocan 2020, all cancers [cited by 30 April, 2021]. Available from: gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.

Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2020;30:1:22-8. doi:10.1016/j.tcm2019.01.006.

Stiller CA. Global Burden Of Childhood Cancer: Growing, But Controllable. The Lancet Oncology. 2019;20(9):1184-5. doi:10.1016/s1470-2045(19)30163-9.

Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer [serial online]. PLoS One. 2010;5:e9584. doi:10.1371/journal.pone.0009584.

Howlader N, Ries LAG, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102:1584-98. doi:10.1093/jnci/djq366.

Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294:1255-9. doi:10.1001/jama.294.10.1255.

Dent S, Liu P, Brezden-Masley C, Lenihan D. Cancer and Cardiovascular Disease: The Complex Labyrinth. J Oncol. 2015;2015:516450. doi:10.1155/2015/516450.

Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19:48-79. doi:10.7812/TPP/14-241.

Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin. 2012;62:220-41. doi:10.3322/caac.21149.

Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504-12. doi:10.1016/j.jacc.2012.07.068.

Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293-305. doi:10.1093/jnci/djs317.

Aleman BM, Moser EC, Nuver J, et al. Cardiovascular disease after cancer therapy. EJC Suppl. 2014;12:18-28. doi:10.1016/j.ejcsup.2014.03.002.

Cardinale D, Lacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026.

Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39. doi:10.3389/fonc.2015.00039.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi:10.3322/caac.21254.

Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547-58. doi:10.1038/nrcardio.2015.65. Erratum in: Nat Rev Cardiol. 2015;12(11):620.

Ali MK, Ewer MS, Gibbs HR, et al. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer.1994;74:182-8.

Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3(2):e000665. doi:10.1161/JAHA.113.000665.

Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102-11. doi:10.1093/eurheartj/ehs181.

Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumabrelated cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422-8. doi: 10.1200/JCO.2009.26.0463.

Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808-15.

Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.

Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218-27. doi:10.1200/JCO.2013.51.1055.

Moses H3rd, Matheson DH, Cairns-Smith S, et al. The anatomy of medical research: US and international comparisons. JAMA. 2015;313:174-89. doi:10.1001/jama.2014.15939.

Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138:470- 84. doi:10.1016/j.pharmthera.2013.03.005.

Brana I, Zamora T, Oristell G, Tabernero J. Side effects of medical cancer therapy. Cardiotoxicity. 2018;14:406. doi:10.1007/978-3-31970253-7-14.

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardology. 2020;17(8):474-502. doi:10.1038/s41569-020-0348-1.

Araujo-Gutierrez R, Ibarra-Cortez SH, Estep JD, et al. Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. Cardiooncology. 2018;4:3. doi:10.1186/s40959-018-0029-y.

Матяш М.Г., Кравчук Т.Л., Высоцкая В.В. и др. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008;6:66-75.

Matyash MG, Kravchuk TL, Vysotskaya VV, et al. Anthracycline-induced cardiotoxicity: mechanisms of development and clinical manifestations. Siberian Journal of Oncology. 2008;6:66-75. (In Russ.)

Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007;7:61-6. doi:10.1007/s12012-007-0016-2.

Шуйкова К.В., Емелина Е.И., Гендлин Г.И., Сторожаков Г.И. Кардиотоксичность современных химиотерапевтических препаратов. Атмосфера. Новости кардиологии. 2012;3:9-19.

Shuykova KW, Emelina EI, Gendlin GE, Storozhakov GI. Cardiotoxicity of modern chemotherapeutic drugs. Atmosphere. Cardiology news. 2012;3:9-19 (In Russ.)

Гендлин Г.Е., Емелина Е.И., Никитин И. Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017;3:145-54. doi:10.15829/1560-4071-2017-3-145-154.

Gendlin GE, Emelina EI, Nikitin IG, Vasyuk YA. Modern view on cardiotoxicity of chemotherapeutic in oncology including anthracyclines. Russian Journal of Cardiology. 2017;3:145-54 (In Russ.) doi:10.15829/1560-4071-2017-3-145-154.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-47. doi:10.1016/j.jacc.2009.02.050.

Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicininduced cardiotoxicity. Nat Med. 2012;18:1639-42. doi:10.1038/nm.2919.

Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229. doi:10.1124/pr.56.2.6.

Delemasure S, Vergely C, Zeller M, et al. Prévention de la cardiotoxicité des anthracyclines: approche fondamentale des mécanismes mis en jeu; relations avec les données cliniques [Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data]. Ann Cardiol Angeiol (Paris). 2006;55(2):104-12. French. doi:10.1016/j.ancard.2006.02.005.

Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol. 2006;329(9):657-68. doi:10.1016/j.crvi.2005.08.007.

Jeyaseelan R, Poizat C, Wu HY, Kedes L. Molecular mechanisms of doxorubicininduced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem. 1997;272:5828-32.

Pelikan PC, Weisfeldt M, Jacobus WE et al. Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol. 1986;8:1058-66.

Nicolay K, Aue WP, J. Seelig et al. Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31PNMR and implications for adriamycininduced cardiotoxicity. Biochim Biophys Acta. 1987;929:5-13.

Eidenschink AB, Schroter G, Muller-Weihrich S, Stern H. Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young. 2000;10:610-7.

Praet M, Ruysschaert JM. In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives. Biochim Biophys Acta. 1993;1149:79-85.

Muraoka S, Miura T. Inactivation of mitochondrial succinatede-hydrogenase by adriamycin activated by horseradish peroxidase and hydrogen peroxide. Chem Biol Interact. 2003;145:67-75.

Zhou S, Starkov A, Froberg MK, et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-7.

Lopaschuk GD, Belke DD, Gamble, J et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263-76.

Bordoni A, Biagi P, Hrelia S. The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim Biophys Acta. 1999; 1440:100-6.

Hong, YM, Kim HS, Yoon HR. Serum lipid and fatty acid profiles in adriamycin -treated rats after administration of L-carnitine. Pediatr Res. 2002;51:249-55.

Wakasugi S, Fischman AJ, Babich JW, et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med. 1993;34:1529-35.

Hrelia S, Fiorentin ID, Maraldi T, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002;1567:150-6.

Васюк Ю.А., Школьник Е.Л., Несветов В.В. и др. Нарушения метаболизма миокарда на фоне химиотерапевтического лечения, а также возможности их коррекции. CardioСоматика. 2013;(4):20-4.

Vasyuk YuA, Shkolnik EL, Nesvetov VV, et al. Disorders of myocardial metabolism against the background of chemotherapeutic treatment, as well as the possibility of their correction. CardioSomatics. 2013;(4):20-4. (In Russ.)

Tokarska-Schlattner M, Wallimann T, Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol. 2002;61:516-23.

Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей. 2016;15(1):50-7. doi:10.18087/rhj.2016.2115.

Seliverstova DV, Evsina OV. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016;15:50-7. (In Russ.) doi:10.18087/rhj.2016.2115.

van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006;4:CD005006.

Wadugu B, Kühn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 2012;302:H2139-H2147. doi:10.1152/ajpheart.00063.2012.

de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-51. doi:10.1016/j.ejca.2007.06.024.

Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859-65. doi:10.1200/JCO.2006.09.1611.

Herrmann J. Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system? Curr Oncol Rep. 2016;18:33. doi:10.1007/s11912-016-0514-0.

Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-49. doi:10.1056/NEJMra0706596.

Nazer B, Hamphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Circulation. 2011;124(15):1687-91. doi:10.1161/CIRCULATIONAHA.110.992230.

Hayman SR, Leung N, Grande JP. Garovic VD. VEGF inhibition, hypertension and renal toxicity. Curr Oncol Rep. 2012;14(4):285-94.

Kappers MN, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endotelin-1 levels. Hypertension. 2010;56(4):675-81. doi:10.1161/HYPERTENSIONAHA.109.149690.

Verdonk K, Saleh L, Lankhorst S, et al. Association studies suggest a key role for endotelin-1 in the pathogenesis of preeclampsia and the accompaying renin-angiotensinaldosterone system suppression. Hypertension. 2015;65(6):1316-23. doi:10.1161/HYPERTENSIONAHA.115.05267.

Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927- 34. doi:10.1093/annonc/mdm550.

Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefication during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470- 6. doi:10.1158/1078-0432.ССR-07-5050.

Touyz RM, Lang NN, Herrmann J, et al. Recent advances hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220- 6. doi:10.1161/HYPERTENSIONAHA.117.08856.

Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332-44. doi:10.1038/nrc2106.

Garcia-Alvarez A, Garcia-Albeniz X, Esteve J, et al. Cardiotoxicity of tyrosinekinase-targeting drugs. Cardiovasc Hematol Agents Med Chem. 2010;8:11-21. doi:10.2174/187152510790796192.

Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-9. doi:10.1016/S0140-6736(07)61865-0.

Tajik R, Saadat H, Taherkhani M. Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. Am Heart Hosp J. 2010;8:2E111-2. doi:10.15420/ahhj.2010.8.2.111.

Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6:1249-69. doi:10.1586/14737140.6.9.1249.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. European Heart Journal. 2016;37:2768-801. doi:10.1093/eurheartj/ehw211.

Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5(6):791-809. doi:10.1517/14740338.5.6.791.

Казюлин А.Н., Вельшер Л.З., Королева И.А., Кучерявый Ю.А. Кардиотоксичность при проведении химиотерапии онкологических заболеваний. Медицина критических состояний. 2010;1:62-70.

Kazyulin AN, Velsher LZ, Koroleva IA, Kucheryavy YuA. Cardiotoxicity during chemotherapy of oncological diseases. Critical condition medicine. 2010;1:62-70. (In Russ.)

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi.10.1002/oncr.11407.

Curigliano G, Lenihan D, Fraley M, et al. Management of cardiac diseases in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90. doi:10.1016/j.annonc.2019.10.023.

Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-9.

Perez EA, Suman VJ, Davidson NE, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004;22:3700-4.

Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist. 2007;12:1124-33. doi:10.1634/theoncologist.12-9-1124.

Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer: therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435-41. doi:10.1016/j.jacc.2007.06.037.

Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864-71.

Fumoleau P, Roche H, Kerbrat Р, et al. Long-term cardiac toxicity after adjuvant epirubicinbased chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006; 7:85-92. doi:10.1093/annonc/mdj034.

Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Prat. 2017;4:1:33-41. doi:10.1530/ERP-17-0013.

Lyon A, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-60. doi:10.1002/ejhf.1920.

Eckel RH, Jakicic JMA, Jesus JM, et al. 2013AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129 (25Suppl2):S76-99. doi:10.1161/01.cir.0000437740.48606.dl.

Plana J, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal. Cardiovascular Imaging. 2014;15(10):1063-93. doi:10.1093/ehjci/jeu192.

Murbraech K, Wethal T, Smeland KB, et al. Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study. JACC Cardiovasc Imaging. 2016;9:230-9. doi:10.1016/j.jcmg.2015.06.028.

Epirubicin Hydrochloride for Injection [package insert]. Mayne Pharma Limited Mulgrave, VIC 3170, Australia. 2006.

Cyclophosphamide [package insert]. Baxter Healthcare Corporation Deerfield, IL 60015 USA. 2013.

Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31-6.

Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263-30.

Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021-4.

Yanamandra U, Gupta S, Khadwal A, Malhotra P. Melphalan-induced cardiotoxicity: ventricular arrhythmias. BMJ Case Rep. 2016;2016:bcr2016218652. doi:10.1136/bcr2016-218652.

Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17:729-36.

Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol. 1994;10:861-4.

Killu A, Madhavan M, Prasad K, Prasad A. 5-fluorouracil induced pericarditis. BMJ Case Rep. 2011;2011:bcr0220113883. doi:10.1136/bcr.02.2011.3883.

Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13:484-5.

Hussein MA, Gundacker H, Head DR, et al. Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706. Leukemia 2005;19:1880-6.

100

Decitabine (Dacogen) [package insert]. MGI PHARMA, INC., Bloomington, MN 55437. 2006.

101

Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-13. doi:10.1056/NEJMoa043681.

102

Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704-12.

103

Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;(15):117-30.

104

Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70:690-1.

105

Vinblastine [package insert]. Bedford Laboratories, Bedford, Ohio 44146. 2012.

106

Rituximab [package insert]. Genentech, Inc. A Member of the Roche Group,1 DNA Way, South San Francisco, CA. 2010.

107

Ofatumumab (Arzerra) [package insert]. GlaxoSmithKline Research Triangle Park, NC 27709. 2009.

108

Alemtuzumab (Campath) [package insert]. Millennium and ILEX Partners, LP Cambridge, MA 02142. 2001.

109

Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84-95. doi:10.1161/CIRCULATIONAHA.108.776831.

110

Li W, Croce K, Steensma DP, et al. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J Am Coll Cardiol. 2015; 66(10):1160-78. doi:10.1016/j.jacc.2015.07.025.

111

Pertuzumab (Perjeta) [package insert]. Genentech, Inc. A Member of the Roche Group, 1 DNA Way, South San Francisco, CA. 2012.

112

Trastuzumab (Herceptin) [package insert]. Genentech, Inc. 1 DNA Way, South San Francisco, CA. 2010.

113

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.

114

Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703. doi:10.1056/NEJMoa1210093.

115

Bronte E, Bronte G, Novo G et al. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6(34):35589- 601. doi:10.18632/oncotarget.5853.

116

Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33(35):4210-8. doi:10.1200/JCO.2015.62.4718.

117

Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83(6):679-86. doi:10.4065/83.6.679.

118

Battisti NML, Tong D, Ring A, Smith I. Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401-8. doi:10.1007/s10549-019-05406-6.

119

Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;22;369(8):722-31. doi:10.1056/NEJMoa1303989.

120

Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-96. doi:10.1056/NEJMoa1306494.

121

Sudasena D, Balanescu DV, Donisan T, et al. Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovasc Toxicol. 2019;19(4):382-7. doi:10.1007/s12012-018-9499-2.

122

Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol. 2014;10(12):1981-92. doi:10.2217/fon.14.42.

123

Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. doi:10.1186/1471-2407-12-231.

124

Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med. 2012;367(2):107-14. doi:10.1056/NEJMoa1203421.

125

Axitinib (Inlyta) [package insert]. Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, USA. 2012.

126

Nilotinib (Tasigna) [package insert]. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936, USA. 2010.

127

Ibrutinib (Ibruvica) [package insert]. Pharmacyclics, Inc. Sunnyvale, CA USA 94085, 2015.

128

Ganatra S, Majithia A, Shah S. Challenges in ibrutinib associated atrial fibrillation. J Am Coll Cardiol. 2017;11:2308.

129

Santoni M, Guerra F, Conti A, et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev. 2017;59:123-31. doi:10.1016/j.ctrv.2017.07.006.

130

Regorafenib (Stivarga) [package insert]. Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ 07470, USA. 2012.

131

Imatinib [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2001.

132

Ziv-aflibercept (Zaltrap) [package insert]. Sanofi-aventis U.S. LLC, Bridgewater, NJ 08807, USA. 2012.

133

Cabozantinib (Cambometyx) [package insert]. Exelixis, Inc. South San Francisco, CA 94080 USA. 2016.

134

Mak IT, Kramer JH, Chmielinska JJ, et al. EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J Cardiovasc Pharmacol. 2015;65:54-61. doi:10.1097/FJC.0000000000000163.

135

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. doi:10.1200/JCO.2006.07.9525.

136

Erlotinib (Tarceva) [package insert]. OSI Pharmaceuticals Inc., Melville, NY 11747, USA. 2010.

137

Tang XM, Chen H, Liu Y et al. The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine (Baltimore). 2017;96:e5946. doi:10.1097/MD.0000000000005946.

138

Ceritinib (Zykadia) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

139

Crizotinib (Xalkori) [package insert]. Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, USA 2012.

140

Vemurafenib (Zelboraf) [package insert]. Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080, USA. 2016.

141

Johnson DB, Balko JM, Compton ML et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375:1749-55. doi:10.1056/NEJMoa1609214.

142

Mahmood SS, Fradely MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64. doi:10.1016/j.jacc.2018.02.037.

143

Ganatra S, Neilan TG. Immune Checkpoint Inhibitor Associated Myocarditis. Oncologist. 2018 Aug;23(8):879-86. doi:10.1634/theoncologist.2018-0130.

144

Bortezomib [package insert]. Millennium Pharmaceuticals Inc., 40 Landsdowne Street, Cambridge, MA 02139, USA. 2014.

145

Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11:228-36. doi:10.1016/j.clml.2011.03.006.

146

Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753-61. doi:10.3324/haematol.2013.089334.

147

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-52. doi:10.1056/NEJMoa1411321.

148

Everolimus [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA 2010.

149

Temsirolimus (Torisel) [package insert]. Wyeth Pharmaceuticals Inc, Philadelphia, PA 19101, USA. 2015.

150

Lenalidomide (Revlimid) [package insert]. Celgene Corporation, Summit, NJ 07901, USA. 2017.

151

Thalidomide [package insert]. In. Summit, NJ 07901, USA: Celgene Corporation 2014.

152

Pomalidomide [package insert]. Celgene Corporation, Summit, NJ 07901, USA. 2013.

153

Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-52. doi:10.1634/theoncologist.12-10-1247.

154

Belinostat (Beleodaq) [package insert]. Spectrum Pharmaceuticals, Inc., Irvine, CA 92618, USA. 2014.

155

Tamoxifen [package insert]. In. Wilmington, Delaware 19850, USA: AstraZeneca Pharmaceuticals LP 2004.

156

Toremifene [package insert]. In. Mephis, TN 38103, USA: GTx, Inc. 2011.

157

Anastrozole (Arimidex) [package insert]. In. Wilmington, DE 19850, USA: AstraZeneca Pharmaceuticals LP 2009.

158

Letrozole (femara) [package insert]. In. East Hanover, New Jersey, 07936, USA: Novartis Pharmaceuticals Corporation 2014.

159

Exemestane (Aromasin) [package insert]. In. NY 10017, USA: Pharmacia & Upjohn Co., Division of Pfizer Inc, NY 2011.

160

Goserelin (Zoladex) [package insert]. In. Wilmington, DE 19850, USA: AstraZeneca Pharmaceuticals LP 2015.

161

Leuprolide (Lupron) [package insert]. In. North Chicago, IL 60064, USA: AbbVie Inc. 2014.

162

Flutamide [package insert]. Schering Corp., Kenilworth, NJ 07033, USA. 2001.

163

Bicalutamide [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA. 2015.

164

Nilutamide [package insert]. ANI Pharmaceuticals, Inc., Baudette, MN 56623, USA. 2015.

165

Tisagenlecleucel (Kymriah) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

166

Axicabtagene ciloleucel (Yescarta) [package insert]. Kite Pharma, Inc., Santa Monica, CA 90404, USA. 2017.

167

Ribociclib (Kisqali) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

168

Didagelos M, Boutis A, Diamantopoulos N, et al. Bleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumor. Hippokratia. 2013;17:187-8.

169

Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep. 1980;64:1159-60.

170

Simbre IV, Adams MJ, Deshpande SS, et al. Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med. 2001;3:93-505.

171

Kathirgamanathan K, Angaran P, Lazo-Langner A, Gula LJ. Cardiac conduction block at multiple levels caused by arsenic trioxide therapy. Can J Cardiol. 2013;29:130.e5-6. doi:10.1016/j.cjca.2012.04.004.

172

Popat S, Smith IE. Therapy insight: anthracyclines and trastuzumab-the optimal managemtnt of cardiotoxic side effects. Nat.Clin.Prac. Oncol. 2008;5:6,324-35. doi:101038/ncponc1090.

173

McGovan JV, Chung R, Mauluk A, et al. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63-75. doi:10107/s10557-16-6711-0.

174

Mousavi N, Tan TC, Ali M, et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015;16(9):977-84. doi:10.1093/ehjci/jev113.

175

Fei HW, Ali MT, Tan TC, et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography. 2016;33(4):519-26. doi:10.1111/echo.13168.

176

Васюк Ю.А., Ющук Е.Н., Несветов В.В. Кардиоонкология: новый вызов нашего времени. Сердечно-сосудистые осложнения противоопухолевого лечения. М.: Клинмедконсалтинг; 2019. c. 100.

Vasyuk YuA, Yushchuk EN, Nesvetov VV. Cardioncology: a new challenge of our time. Cardiovascular complications of antitumor treatment. M.: Klinmedconsulting; 2019. p. 100. (In Russ.)

177

Lange SA, Jung J, Jaeck A, et al. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients. Cardiovasc Toxicol. 2016;16(2):193-206. doi:10.1007/s12012-015-9328-9.

178

Boyd A, Stoodley P, Richards D, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS One. 2017;13;12(4):e0175544. doi:10.1371/journal.pone.0175544.

179

Ho E, Brown A, Barrett P, et al. Subclinical anthracycline and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010;96(9):701-7. doi:10.1136/hrt.2009.173997.

180

Serrano JM, González I, Del Castillo S, et al. Diastolic Dysfunction Following AnthracyclineBased Chemotherapy in Breast Cancer Patients: Incidence and Predictors. Oncologist. 2015;20(8):864-72. doi:10.1634/theoncologist.2014-0500.

181

Yu AF, Ho AY, Braunstein LZ, et al. Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. J Am Soc Echocardiogr. 2019;32(4):521-8. doi:10.1016/j.echo.2018.12.009.

182

Вельшер Л.З., Казюлин А.Н., Королева А.Н. Кардиотоксичность при химиотерапии рака молочной железы по данным ретроспективного мультицентрового “случай-контроль” исследования. Вестник хирургии им. И.И. Грекова. 2010;169(4):17-21.

Welsher LZ, Kazyulin AN, Koroleva AN. Cardiotoxicity in breast cancer chemotherapy according to the data of a retrospective multicenter “case-control” study. Bulletin of Surgery named after I.I. Grekov. 2010;169(4):17-21. (In Russ.)

183

Song L, Brezden-Masley C, Ramanan V, et al. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab. Am J Cardiol. 2019;1;123(7):1173-9. doi:10.1016/j.amjcard.2018.12.046.

184

Lancellotti PN, Komo VT, Badano LP, et al. 2013 Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26(9):1013-32. doi:10.1016/j.echo.2013.07.005. Erratum in: J Am Soc Echocardiogr. 2013;26(11):1305.

185

Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-20. doi:10.1016/j.jacc.2009.03.095.

186

Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984;2(2):112-7. doi:10.1200/JCO.1984.2.2.112.

187

Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738-44.

188

Takigiku K, Takeuchi M, Izumi C, et al; JUSTICE investigators. Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study. Circ J. 2012;76(11):2623-32. doi:10.1253/circj.cj-12-0264.

189

Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493-8. doi:10.1016/j.echo.2013.02.008.

190

Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63:2751-68. doi:10.1016/j.jacc.2014.01.073.

191

Australian Government, National Health and Medical Research Council, Department of Industry. Tasmanian Study of Echocardiographic detection of Left ventricular dysfunction (TAS-ELF). Available from: www.australianclinicaltrials.gov.au/node/1716.

192

Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. J Cardiovasc Pharmacol Ther. 2019;24(3):233-41. doi:10.1177/1074248418821721.

193

Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375-80. doi:10.1016/j.amjcard.2011.01.006.

194

Sawaya H, Sebag IA, Plana JC, et al. Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients treated with Anthracyclines, Taxanes and Trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. doi:10.1161/CIRCIMAGING.112.973321.

195

Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicini-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1-7. doi:10.1016/j.ahj.2010.05.037.

196

Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117(3):568-75. doi:10.1172/JCI31044.

197

Mondillo S, Galderisi M, Mele D, et al. Echocardiography Study Group of the Italian Society of Cardiology. Speckle-tracking echocardiography: A new technique for assessing myocardial function. J Ultrasound Med. 2011;30:71-83. doi:10.7863/jum.2011.30.1.71.

198

Tian M, Nishijima Y, Asp ML, et al. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol. 2010;37:347-53. doi:10.3892/ijo_00000683.

199

Negishi K, Negishi T, Haluska BA, et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-31. doi:10.1093/ehjci/jet159.

200

Stoodley PW, Richards DA, Hui R, et al. Two dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011;12(12):945-52. doi:10.1093/ejechocard/jer187.

201

Song FY, Shi J, Guo Y, et al. Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy. Int J Cardiovasc Imaging. 2017;33(6):857-68. doi:10.1007/s10554-017-1082-6.

202

Florescu M, Magda LS, Enescu OA, et al. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83-92. doi:10.1016/j.echo.2013.10.008.

203

Motoki H, Koyama J, Nakazawa H, et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13(1):95- 103. doi:10.1093/ejechocard/jer172.

204

Mornoş C, Manolis AJ, Cozma D, et al. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity. Hellenic J Cardiol. 2014;55(3):235-44.

205

Li VW, Liu AP, So EK, et al. Two- and three-dimensional myocardial strain imaging in the interrogation of sex differences in cardiac mechanics of long-term survivors of childhood cancers. Int J Cardiovasc Imaging. 2019;35(6):999-1007. doi:10.1007/s10554-019-01573-1.

206

Erven K, Florian A, Slagmolen P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1172-8. doi:10.1016/j.ijrobp.2012.09.022.

207

Tuohinen SS, Skyttä T, Poutanen T, et al. Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2017;33(4):463-72. doi:10.1007/s10554-016-1021-y.

208

Cuppone F, Bria E, Verma S, et al. Do adjuvant aromstase inhibitirs increase the cardiovascular risk in poctmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260-72.

209

de Geus-Oei L-F, Mavinkurve-Groothuis AMC, Bellersen L, et al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. Journal of Nuclear Medicine. 2011;52(4):560-71. doi:10.2967/jnumed.110.082784.

210

Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of (123) I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6(7):772-84. doi:10.1016/j.jcmg.2013.02.007.

211

Panjrath GS, Jain D. Monitoring chemotherapyinduced cardiotoxicity: role of cardiac nuclear imaging. Journal of Nuclear Cardiology. 2006;13 (3):415-26.

212

Wakasugi S, Fischman AJ, Babich JW, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34(8):1283-6.

213

Jeon TJ, Lee JD, Ha JW, et al. Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. Eur J Nucl Med. 2000;27(6):686-93.

214

Niitsu N, Yamazaki J, Umeda M. Clinical usefulness of 123I-BMIPP (beta-methyl iodophenyl pentadecanoic (acid) myocardial SPECT in patients with hematological malignancies with adriamycininduced cardiomyopathy. Gan To Kagaku Ryoho. 1996;23(13):1793-7.

215

Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson. 2004;6:727-65.

216

Armstrong AC, Gidding S, Gjesdal O, et al. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012;5:837-48. doi:10.1016/j.jcmg.2012.06.003.

217

Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review. Circulation: Cardiovascular Imaging. 2013;6(6):1080-91. doi:10.1161/CIRCIMAGING.113.000899.

218

Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging — a pilot study. The American Heart Journal. 2001;141(6):1007-13.

219

Fallah-Rad N, Lytwyn M, Fang T, et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. Journal of Cardiovascular Magnetic Resonance. 2008;10(8):729-40. doi:10.1186/1532-429X-10-5.

220

Drafts BC, Twomley KM, D’Agostino RJr, et al. Low to moderate dose anthracyclinebased chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Journal of the American College of Cardiology: Cardiovascular Imaging. 2013;6(8):877-85. doi:10.1016/j.jcmg.2012.11.017.

221

Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. Journal of Clinical Oncology. 2012; 30(23):2876-84. doi:10.1200/JCO.2011.40.3584.

222

Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-54. doi:10.1161/01.CIR.0000130926.51766.CC.

223

Cardinale D, Caruso V, Cipolla CM. The breast cancer patient in the cardiooncology unit. Review. J Thorac Dis. 2018;10(Suppl 35):S4306-S4322. doi:10.21037/jtd.2018.10.06.

224

Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809. doi:10.1016/j.jacc.2013.10.061.

225

Liu FT Hsu DK, Zuberi RI, et al. Expressionand function of galectin-3, a beta-galactosidebinding lectin, in humanmonocytes andmacrophages. Am J Pathol. 1995;147(4):1016-28.

226

Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230(1):160-71. doi:10.1111/j.1600-065X.2009.00794.x.

227

Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, et al Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013;169(3):177-82. doi:10.1016/j.ijcard.2013.08.081.

228

Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77(5):598-625. doi:10.1189/jlb.1204697.

229

Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004;37:902-11. doi:10.1016/j.freeradbiomed.2004.06.003.

230

Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94(1):437-44.

231

Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 2008;52(18):1458-65. doi:10.1016/j.jacc.2008.07.042.

232

Shah RV, Januzzi JL Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7(1):9-14. doi:10.1007/s11897-010-0005-9.

233

Чазова И.Е., Виценя М.В., Агеев Ф.Т. и др. Сердечно-сосудистые осложнения противоопухолевой терапии. Москва, М. Гарант, 2019. c. 225.

Chazova IE, Vitsenya MV, Ageev FT, et al. Cardiovascular complications of antitumor therapy. Moscow, M. Garant, 2019. p. 225. (In Russ.)

234

Pacciarini MA, Barbieri B, Colombo T, et al. Distribution and antitumor activity of adriamicin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep. 1978;62:791-800.

235

Scott JM, Khacoo A, Mackey JR, et al. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlyng mechanisms. Circulation. 2011;124:642-50. doi:10.1161/CIRCULATIONAHA.111.021774.

236

Kalam K, Marwick TH. Role cardioprotective therapy or prevention of cardiotoxisity with chemotherapy: a systematic review and meta-analisis. Eur J Cancer. 2013;49:2900-9. doi:10.1016/j.ejca.2013.04.030.

237

U.S. Food and Drug Administration. Drug Safety and Availability. FDA statement and dexrazoxan. Jul 20, 2011. Available at: http: www.fda/Drugs/DrugSafety/ucm263729.htm

238

Lyu YL, Kerrigan JE, Lin SP, et al. Topoisomerase II IIβ mediated DNA Double-strand breaks: Implications in doxorubicin cardiotoxisity and prevention by dexrazoxsane. Cancer Res. 2007;67:8839-46. doi:10.1158/0008-5472.CAN-07-1649.

239

Vejpongsa P, Yeh ETH. Prevention of anthracycline-Induced cardiotoxisity challenges and opportunities. J Am Coll Cardiol. 2014;64:938-45. doi:10.1016/j.jacc.2014.06.1167.

240

Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxsane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-32.

241

Raimondi S, Botteri E, Munzone E, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer. 2016;139:212-19. doi:10.1002/ijc.30062.

242

Asanuma H, Minamino T, Sanada S, et al. Beta-adrenoreceptor blocker carvedilol provides cardioprotection via an adrenosine-dependent mechanism in ischemic canine hearts. Circulation. 2004;109:2773-9. doi:10.1161/01.CIR.0000130917.12959.04.

243

Kim AM, Tilley DG, Chen J, et al. Beta- blocker alprenolol and carvedilol stimulate betaarrestine-mediated EGFR transactivation. Proc Natl Acad Sci USA. 2008;105:1455-60. doi:10.1073/pnas.0804745105.

244

Oliveria PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004;200:159-68. doi:10.1016/j.taap.2004.04.005.

245

Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-62. doi:10.1016/j.jacc.2006.07.052.

246

El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18(8):607-13. doi:10.1016/j.cardfail.2012.06.416.

247

Avila VS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. J Am Coll Cardiol. 2018;71:2281- 90. doi:10.1016/j.jacc.2018.02.049.

248

Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline- induced cardiomyophaty: a randomized control study. Int J Cardiol. 2013;167:2306-10. doi:10.1016/j.ijcard.2012.06.023.

249

Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effects of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallele-group, randomized controlled study with 36-month follow-up. Am J Hematol. 2010;85:894-6. doi:10.1002/ajh.21840.

250

Gulaty G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjvant breast cancer therapy (PRADA): 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671-80. doi:10.1093/eurheartj/ehw022.

251

Choe JY, Combs AB, Folkers K. Potentiation of the toxicity of adriamicin by propranolol. Res Commun Chem Pathol Pharmacol. 1978;21:577-80.

252

Abd El-Aziz MA, Othman Al, Amer M, et al. Potential protective role of angiotensinconverting enzyme inhibitor captopril and enalapril against adriamicin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469-743. doi:10.1002/jat.782.

253

Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002;88(2):183-8. doi:10.1254/jjp.88.183.

254

Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142:396-403.e3. doi:10.1016/j.jtcvs.2010.07.097.

255

Lemmens K, Segers VF, Demolder M, et al. Role of neuregulin-1/ ErbB2 signaling in endothelium-cardiomiocite cross-talk. Biol Chem. 2006;281:19469-77. doi:10.1074/jbc.M600399200.

256

Cernecka H, Ochodnicka-Mackovicova K, Kucerova D, et al. Enaprilat increases PPARbeta/ delta expression, without influence on PPRalpha and PPRgamma, and modulate cardiac function in sud-acute model of daunortubicini-induced cardiomyopathy. Eur J Pharmacol 2013;714:472-7. doi:10.1016/j.ejphar.2013.06.040.

257

Tokudome T, Mizushige K, Noma T, et al. Prevention of doxorubicin (Adriamycin)-induced cardiomyophtaty by simultaneous administration of angiotensin–converting enzyme inhibition assessed by acoustic densitometry. J Cardiovasc Pharmacol. 2000;36:361-8. doi:10.1097/00005344-200009000-00012.

258

Boucek RJ Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3(4):319-29. doi:10.1385/ct:3:4:319.

259

Subissi A, Evangelista, Giachetti A, Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1999;2:115-33.

260

Chopra M, Beswick H, Clapperton M, et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulphydryl dependent, but lipid peroxidation is inhibited by both sulphydryl- and nonsulphydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol. 1992;19:330-40.

261

Napoli C, Cicala C, D’Armiento FP, et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen. Pharmacol. 1999;33:467-77.

262

Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulphydrylcontaining enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 1990;40:2169-75.

263

Li T, Danelisen I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc. Res. 2000;46:523- 30. doi:10.1016/s0008-6363(00)00039-0.

264

Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapyinduced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial. J Am Coll Cardiol. 2013;61:2355-62. doi:10.1016/j.jacc.2013.02.072.

265

Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracyclin-induced cardiomyopathy. Eur J Heart Fail. 2015;17:81-9. doi:10.1002/ejhf.196.

266

Seicean S, Seiceаn A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patient with breast cancer receiving anthracycline chemotherapy: an observation clinical cohort study. J Am Coll Cardiol. 2012;60:2384-90. doi:10.1016/j.jacc.2012.07.067.

267

Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988-9. doi:10.1016/j.jacc.2011.05.025.

268

Chotenimitkhun R, D’Agostino R, Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31:302-7. doi:10.1016/j.cjca.2014.11.020.

269

Colak MC, Parlakpinar H, Tasdemir S, et al. Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol. 2012;31(9):945-54. doi:10.1177/0960327112438288.

270

Решина И.В., Калягин А. Н., Середа Н.Н. Применение ивабрадина с целью купирования кардиотоксических эффектов у больных онкологическими заболеваниями, получающих полихимиотерапию. Consilium Medicum. 2010;12(5):110-3.

Reshina IV, Kalyagin AN, Sereda NN. The use of ivabradine for the purpose of relieving cardiotoxic effects in patients with oncological diseases receiving polychemotherapy. Consilium Medicum. 2010;12(5):110-3. (In Russ.)

271

Васюк Ю.А., Несветов В.В., Школьник Е.Л. и др. Возможности селективного ингибитора ионных f-каналов синусового узла ивабрадина в профилактике антрациклиновой кардиотоксичности у больных раком молочной железы. Рациональная фармакотерапия в кардиологии. 2017;13(2):184-90.

Vasyuk YuA, Nesvetov VV, Shkolnik EL, et al. Possibilities of selective inhibitor of ion f-channels of the sinus node ivabradine in the prevention of anthracycline cardiotoxicity in breast cancer patients. Rational pharmacotherapy in cardiology. 2017;13(2):184-90. (In Russ.)

272

Amal Mohamed Moustafa Y, Shalahy Amany Abd Elrahman M. Impact of trimetazidine on doxorubicin induced acute cardiotoxicity in mice: a biochemical and electron microscopic study. Egyptian J Histology. 2006; 29(1):125-36.

273

Tallarico D, Rizzo V, Di Maio F. Myocardial cytoprotection by trimetazidine against anthracycline-nduced cardiotoxicity in anticancer chemotherapy. Angiology. 2003;54(2):219-27. doi:10.1177/000331970305400212.

274

Васюк Ю.А., Школьник Е.Л., Несветов В.В. и др. Кардиоонкология: современные аспекты профилактики антрациклиновой кардиотоксичности Кардиология. 2016;56(12):72-9.

Vasyuk YuA, Shkolnik EL, Nesvetov VV, et al. Cardioncology: modern aspects of prevention of anthracycline cardiotoxicity Kardiologija. 2016;56(12):72-9. (In Russ.)

275

Pascale C, Fornengo P, Epifani G, et al. Cardioprotection of trimetazidine and anthracycline- induced acute cardiotoxic effects. Lancet. 2002;359:1153-4. doi:10.1016/S0140-6736(02)08135-7.

276

Калинкина Н.В. Влияние триметазидина на безболевую ишемию миокарда и диастолическую функцию левого желудочка у пациентов, получающих антрациклиновые антибиотики. Вестник неотложной и восстановительной медицины. 2006;2:195-8.

Kalinkina NV. The effect of trimetazidine on pain-free myocardial ischemia and diastolic function of the left ventricle in patients receiving anthracycline antibiotics. Bulletin of Emergency and Restorative Medicine. 2006;2:195-8. (In Russ.)

277

Ватутин Н.Т., Калинкина Н.В., Риджок В.В., Столика О.И. Влияние триметазидина на вариабельность сердечного ритма и систолическую функцию левого желудочка у пациентов, получающих антрациклиновые антибиотики. Кровообращение, гемостаз. 2005;3- 4:141-5.

Vatutin NT, Kalinkina NV, Rijok VV, Stolika OI. The effect of trimetazidine on heart rate variability and systolic function of the left ventricle in patients receiving anthracycline antibiotics. Blood circulation, hemostasis. 2005;3-4:141-5. (In Russ.)

278

Tase AG, Man MG, Tase A, Savoiu G. Trimetazidine added-on therapy could lower the risk of incidental left ventricular dysfunction with or without heart failure in epirubicinum recipients for breast cancer. JACC. 2017;69(11), Suppl.:917. doi:10.1016/S0735-1097(17)34306-1.

279

Strumia E. Creatine Phosphate: Pharmacological and Clinical Perspectives. Adv Ther. 2012;29(2):99-123. doi:10.1007/s12325-011-0091-4.

280

Wang W, Zhaoqiang F, Bai J. Cardioprotective effects of creatine phosphate sodium in elderly breast cancer patients under epirubicin adjuvant chemotherapy. Int J Clin Exp Med. 2019;12(10):12418-25. http://www.ijcem.com/files/ijcem0094064.pdf

281

Дербугов В. Н., Потапов А. Л., Потиевская В. И., Хмелевский Я. М. Применение экзогенного фосфокреатина у пациентов пожилого и старческого возраста, оперируемых по поводу колоректального рака. Общая реаниматология. 2017;13(4):38-45. doi:10.15360/1813.9779.2017.4.38.

Derbugov VN, Potapov AL, Potievskaya VI, Khmelevsky YaM. The use of exogenous phosphocreatin in elderly and senile patients operated on for colorectal cancer. General resuscitation. 2017;13(4):38-45. (In Russ.) doi:10.15360/1813.9779.2017.4.38.

282

Zhu Jing, Yao Hong-mei. Influence of creatine phosphate sodium on the quality of life of patients undergoing cancer chemotherapy. Hainan Medical Journal. 2012;23(16):31-6.

283

Elli M, Sungur M, Genç G, et al. The late effects of anticancer therapy after childhood Wilm’s tumor: the role of diastolic function and ambulatory blood pressure monitoring. Jpn J Clin Oncol, 2013;43:1004-11. doi:10.1093/jjco/hyt105.

284

Minotti G. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. J Pharmacol Exp Ther. 2013;346:343-9. doi:10.1124/jpet.113.204057.

285

Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta. 2015;1848:2727-37. doi:10.1016/j.bbamem.2015.01.003.

286

Cappetta D, Esposito G, Coppini R, et al. Effects of ranolazine in a model of doxorubicininduced left ventricle diastolic dysfunction. British Journal of Pharmacology. 2017;174:3696-712. doi:10.1111/bph.13791.

287

Hwang H, Arcidi JMJr, Hale SL, et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation. 2009;120:S16-S21. doi:10.1161/CIRCULATIONAHA.108.844167.

288

Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na (+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330-42. doi:10.1016/j.jacc.2009.12.055.

289

Figueredo VM, Pressman GS, Romero-Corral A, et al. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther. 2011;16:168-72. doi:10.1177/1074248410382105.

290

Coppini R, Ferrantini C, Yao L, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127:575-84. doi:10.1161/CIRCULATIONAHA.112.134932.

291

Williams S, Pourrier M, McAfee D, et al. Ranolazine improves diastolic function in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2014;306:H867-H881. doi:10.1152/ajpheart.00704.2013.

292

De Angelis A, Cappetta D, Piegari E, et al. Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. Int J Cardiol. 2016;217:69-79. doi:10.1016/j.ijcard.2016.04.168.

293

Tocchetti CG, Carpi A, Coppola C, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014;16:358-66. doi:10.1002/ejhf.50.

294

Corradi F, Paolini L, De Caterina R. Ranolazine in the prevention of anthracycline cardiotoxicity. Pharmacol Res. 2014;79:88-102. doi:10.1016/j.phrs.2013.11.001.

295

Negishi T, Thavendiranathan P, Negishi K, Marwick TH; SUCCOUR investigators. Rationale and design of the strain survelliance chemoteraphy for improving cardiovascular outcomes: The tial. JAAC Cardiovasc Imaging. 2018;11:1098-105.

296

Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981-8. doi:10.1161/CIRCULATIONAHA.114.013777.

297

Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:2196- 201. doi:10.1016/j.healun.2004.12.108.

298

Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32:831-41. doi:10.1016/j.cjca.2016.02.078.

299

Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8-158. doi:10.18087/cardio.2475.

Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.

300

Sacks FM, Pfeffer MA, Moye LA, et al.; for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9. doi:10.1056/NEJM199610033351401.

301

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849. doi:10.1371/journal.pone.0029849.

302

Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a metaanalysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606-12. doi:10.1200/JCO.2005.02.7045.

303

Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135:261-9. doi:10.1007/s10549-012-2154-x.

304

Desai P, Chlebowski R, Cauley JA, et al. Prospective analysis of association between statin use and breast cancer risk in the women’s health initiative. Cancer Epidemiol Biomarkers Prev. 2013;22:1868-76. doi:10.1158/1055-9965.EPI-13-0562.

305

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT). https://clinicaltrials.gov/ct2/show/NCT01988571. Accessed June 26, 2017.

306

Виценя М.В., Потехина А.В., Гаврюшина С.В. и др. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы. Эффективная фармакотерапия 2020;16(8):108-20. doi:10.33978/2307-3586-2020-16-18-108-120.

Vitsenya MV Potekhina AV, Gavryushina SV, et al. Prevention and treatment of left ventricular dysfunction and heart failure associated with antitumor therapy: opportunities and prospects. Effective pharmacotherapy 2020;16(8):108-20. (In Russ.) doi:10.33978/2307-3586-2020-16-18-108-120.

307

Vitsenya M, Potekhina A, Gavryushina S, et al. Sacubitril/valsartan improves heart failure functional class, left ventricular systolic and diastolic function and neurohumoral status in patients with anthracycline-induced cardiomyopathy. Eur Heart Journal. 2020;41(Suppl 2):3265. doi:10.1093/ehjci/ehaa946.3265.

308

Rueckert S, Ruechl I, Kachlert S, et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opinion on Biological Therapy. 2005;5(6):853- 66. doi:10.1517/14712598.5.6.853.

309

Seisean S, Seisean A, Alan N, et al. Cardioprotective effects of β-adrenoreceptor blockade inpatients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6:420-6. doi:10.1161/CIRCHEARTFAILURE.112.000055.

310

Slamon D, Eiermann W, Robert N, et al. Breast Cancer international Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl J Med. 2011;365:1273-83.

311

Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novell Therapies in Cardio-oncology Research (MANTICORE 101-Breast). A randomized trial for the prevention of trastuzumab-assosiated cardiotoxicity. J Clin Oncol. 2017;35(8):870-7. doi:10.1200/JCO.2016.68.7830.

312

Oliva S, Cioffi G, Frattini S, et al.; on behalf of the Italian Cardio-Oncological Network. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist. 2012;17:917-24. doi:10.1634/theoncologist.2011-0445.

313

Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-6. doi:10.1200/JCO.2005.13.300.

314

Mackey JR, Clemons M, Côté MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15:24-35.

315

Schmidt AC, Graf Ch, Brixius K, et al. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Invest. 2007;27(12):841-9.

316

Un HH, Kim S, Kuh HJ, Lee JH. Downregulation of BIS sensitizes A549 cells for digoxinmediated inhibition of invasion and migration by the STAT3-dependent pathway. Biochem Biophys Res Commun. 2020;524(3):643-8. doi:10.1016/j.bbrc.2020.01.154.

317

Wang Y, Ma Q, Zhang S, et al. Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. Front Pharmacol. 2020;11:186. doi:10.3389/fphar.2020.00186.

318

Yun HH, Kim S, Kuh HJ, Lee JH. Downregulation of BIS sensitizes A549 cells for digoxinmediated inhibition of invasion and migration by the STAT3-dependent pathway. Biochem Biophys Res Commun. 2020;524(3):643-8. doi:10.1016/j.bbrc.2020.01.154.

319

Villani F, Comazzi R, Di Fronzo G, et al. Evaluation of doxorubicin cardiotoxicity in patients treated intermittently with beta-methyldigoxin. Tumori. 1982;68(4):349-53.

320

Shiga T, Im J, Kikuchi N, Arakawa Y. The Effective Use of Digoxin in a Patient with Metastatic Breast Cancer and Anthracycline-induced Cardiomyopathy. Intern Med. 2021;60(17):2819-23. doi:10.2169/internalmedicine.6787-20.

321

Lenčová-Popelová O, Jirkovský E, Jansová H, et al. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. J Mol Cell Cardiol. 2016;91:92-103. doi:10.1016/j.yjmcc.2015.12.021.

322

Xi L, Zhu SG, Das A, et al. Dietary Inorganic Nitrate Alleviates Doxorubicin Cardiotoxicity: echanisms and Implications. Nitric Oxide. 2012;26(4):274-84. doi:10.1016/j.niox.2012.03.006.

323

Refaie MMM, Shehata S, El-Hussieny M, et al. Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in CyclophosphamideInduced Cardiotoxicity. Cardiovasc Toxicol. 2020;20(1):71-81. doi:10.1007/s12012-019-09535-8.

324

Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-7.

325

Vaklavas C, Lenihan D, Kurzrock R, et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010;15:130-41.

326

Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900-8.

327

Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2:15-25.

328

Khakoo AY Kassiotis CM,Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500-8.

329

Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.

330

Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-32.

331

Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin. 2019;15:487-95. doi:10.1016/j.hfc.2019.06.010.

332

Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenibinduced blood pressure elevations on the first day of treatment.Clin Cancer Res. 2009;15:6250-7.

333

Hamnvik OP, Choueiri TK,Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311-9. doi:10.1002/cncr.28972.

334

Abdel-Qadir H, Ethier JL, Lee DS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120-7. doi:10.1016/j.ctrv.2016.12.002.

335

Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

336

Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1(2):238- 51. doi:10.1016/j.jaccao.2019.11.009.

337

Guglin M, Krischer J,Tamura R, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73:2859-68.

338

Bottinor WJ, Shuey MM, Manouchehri A, et al. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC CardioOncol. 2019;1(1):14-23. doi:10.1016/j.jaccao.2019.07.002.

339

Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38(3):263-5.

340

McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:2471-9. doi:10.1158/1078-0432.CCR-14-2332.

341

Li XY, Sun JF, Hu SQ. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci. 2017;21:1375-83.

342

Catino AB, Hubbard RA,Chirinos JA, et al. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. Circ Heart Fail. 2018;11:e004408. doi:10.1161/CIRCHEARTFAILURE.117.004408.

343

Curwen JO, Musgrove HL, Kendrew J, et al. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant, antihypertensive therapy. Clin Cancer Res. 2008;14:3124-31. doi:10.1158/1078-0432.CCR-07-4783.

344

Marvel FA, Whelton SP, Blumenthal RS. A Cardio-Oncology Cardiovascular Prevention Framework. JACC CardioOncol. 2019;1(2):252-255. doi:10.1016/j.jaccao.2019.11.012.

345

Agarwal M, Thareja N, Benjamin M, et al. Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep. 2018;20(8):65. doi:10.1007/s11912-018-0708-8.

346

Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559-69. doi:10.1016/j.kint.2020.10.026.

346 Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559-69. doi:10.1016/j.kint.2020.10.026.

347

Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926-938. doi:10.1016/j.jacc.2017.06.047.

348

Berton G, Cordiano R, Cavuto F, et al. Neoplastic disease after acute coronary syndrome: incidence, duration, and features: the ABC-4* Study on Heart Disease. J Cardiovasc Med (Hagerstown). 2018;19(10):546-53. doi:10.2459/JCM.0000000000000701.

349

Han XJ, Li JQ, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med. 2020;5(4):221-33. doi:10.1016/j.cdtm.2019.12.007.

350

Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies. The Old and the New — An Evolving Avenue. Circulation. 2016;133(13):1272-89. doi:10.1161/CIRCULATIONAHA.115.018347.

351

Mohanty BD, Mohanty S, Hussain Y, et al. Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge. Future Cardiol. 2017;13(3):247-57. doi:10.2217/fca-2017-0002.

352

Gara E, Csikó KG, Ruzsa Z, et al. Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. Med Oncol. 2019;36(8):72. doi:10.1007/s12032-019-1295-8.

353

Manouchehri A, Kanu E, Mauro MJ, et al. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. Arterioscler Thromb Vasc Biol. 2020;40(2):301-8. doi:10.1161/ATVBAHA.119.313353.

354

Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, nonHDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366. Erratum in: JAMA. 2012;307(16):1694. Erratum in: JAMA. 2012;307(18):1915.

355

Tall AR, Levine RL. Cardiovascular disease: commonality with cancer. Nature. 2017;543:45- 7. doi:10.1038/nature21505.

356

Shen Y, Wang C, Ren Y, Ye J. A comprehensive look at the role of hyperlipidemia in promoting colorectal cancer liver metastasis. J Cancer. 2018;9(16):2981-6. doi:10.7150/jca.25640.

357

Chimento A, Casaburi I, Avena P, et al. Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment. Front Endocrinol (Lausanne). 2019;9:807. doi:10.3389/fendo.2018.00807.

358

Fatehi Hassanabad A. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res. 2019;8(5):692-9. doi:10.21037/tlcr.2019.09.08.

359

Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102-46. doi:10.1124/pr.111.004994.

360

Farooqi MAM, Malhotra N, Mukherjee SD, et al Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2018;13(12):e0209486. doi:10.1371/journal.pone.0209486.

361

Jang HJ, Kim HS, Kim JH, Lee J. The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials. J Clin Med. 2018;7:325. doi:10.3390/jcm7100325.

362

Jian-Yu E, Graber JM, Lu SE, et al. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem. 2018;25:2595-607. doi:10.2174/0929867324666170412145232.

363

Zhang Y, Liang M, Sun C, et al. Statin Use and Risk of Pancreatic Cancer: An Updated Metaanalysis of 26 Studies. Pancreas. 2019;48:142-50. doi:10.1097/MPA.0000000000001226.

364

Nayan M, Punjani N, Juurlink DN, et al. Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treat Rev. 2017;52:105-16. doi:10.1016/j.ctrv.2016.11.009.

365

Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials Drug Des Devel Ther. 2019;13:405-22. doi:10.2147/DDDT.S187690.

366

Jeong GH, Lee KH, Kim JY, et al. Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis. J Clin Med. 2020;9(2):326. doi:10.3390/jcm9020326.

367

Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.

368

Schwartz GG, Steg PG, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107. doi:10.1056/NEJMoa1801174.

369

Asteggiano R, Norbiato C, Marengo S, Parrini I. Cancer and arrhythmias. e-Journal of Cardiology Practice. 2021;19:2020-1.

370

Desai MY, Windecker S, Lancellotti P, et al. Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74:905-27. doi:10.1016/j.jacc.2019.07.006.

371

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021;42(5):507. Erratum in: Eur Heart J. 2021;42(5):546-7. Erratum in: Eur Heart J. 2021 Sep 14.

372

Jakobsen C, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. doi:10.1186/s12885-019-6314-9.

373

Liu Y, Tan D, Shi L, et al. Blueberry anthocyanins enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS One. 2015;10(7):e0127813. doi:10.1371/journal. pone.0127813.

374

Lara PN. The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. Clinical Cancer Research. 2005;11(12):4444-50. doi:10.1158/1078-0432.ccr-04-2602.

375

Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405-11. doi:10.1016/j.jtcvs.2009.02.046.

376

Alexandre J, Molsehi J, Bersell K, et al. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacology & Therapeutics. 2018;189:89-103. doi:10.1016/j.pharmthera.2018.04.009.

377

Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC. Clin. Electrophysiol. 2018;4(12):1491-500. doi:10.1016/j.jacep.2018.06.004.

378

Roselli E, Murthy S, Rice T, et al. Atrial fibrillation complicating lung cancer resection. The Journal of Thoracic and Cardiovascular Surgery. 2005;130(2):438.e1-438.e9. doi:10.1016/j.jtcvs.2005.02.010.

379

Siu C, Tung H, Chu K, et al. Prevalence and Predictors of New-Onset Atrial Fibrillation After Elective Surgery for Colorectal Cancer. Pacing and Clinical Electrophysiology. 2005;28(s1):S120-S123. doi:10.1111/j.1540-8159.2005.00024.

380

Ojima T, Iwahashi M, Nakamori M, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surgery Today. 2013;44(5):839-47. doi:10.1007/s00595-013-0616-3.

381

Васюк Ю.А., Шупенина Е.Ю., Новосел Е.О., Агапов И.С. Нарушения ритма и проводимости сердца как проявления кардиотоксичности противоопухолевого лечения — миф или реальность? Сибирский медицинский журнал. 2020;35(1):13-21. doi:10.29001/2073-8552-2020-35-1-13-21.

Vasyuk YuA, Shupenina EYu, Novosel EO, Agapov IS. Heart rhythm and conduction disorders as manifestations of cardiotoxicity of anticancer treatment: myth or reality? The Siberian Journal of Clinical and Experimental Medicine. 2020;35(1):13-21. (In Russ.) doi:10.29001/2073-8552-2020-35-1-13-21.

382

Farmakis D, Parissis J, Filippatos G. Insights into oncocardiology: atrial fibrillation in cancer. JACC. 2014;63(10):945-53. doi:10.1016/j.jacc.2013.11.026.

383

Lyman GH, Bohlke K, Khorana AA, et.al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654-6. doi:10.1200/JCO.2014.59.7351.

384

Porta-Sanchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J. Am. Heart Assoc. 2017;6(12):e07724. doi:10.1161/JAHA.117.007724.

385

Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38:129-52. doi:10.1007/s40264-014-0258-4.

386

Han J, Lee S, Lee G, et al. Phase I/II study of gefitinib (IressaR) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2015;75(3):475-83. doi:10.1007/s00280-014-2664-9.

387

Fradley M, Viganego F, Kip K, et al. Rates and risk of arrhythmias in cancer survivors with chemotherapy induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart. 2017;4(2):e000701. doi:10.1136/openhrt-2017-000701.

388

Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33-53. doi:10.1016/j.trsl.2020.06.012.

389

Eichinger S. Cancer associated thrombosis: Risk factors and outcomes. Thromb. Res. 2016;140:S12-S17. doi:10.1016/S0049-3848(16)30092-5.

390

Hamza MS, Mousa SA. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. Clin Appl Thromb Hemost. 2020;26: 1076029620954282. doi:10.1177/1076029620954282.

391

Razak NBA, Jones G, Bhandari M, et al. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment Cancers (Basel) 2018;10(10):380. doi:10.3390/cancers10100380.

392

Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. Journal of Cardiology. 2018;72(2):89-93. doi:10.1016/j.jjcc.2018.02.011.

393

Donnellan E, Kevane B, Bird BR, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014;21(3):134-43. doi:10.3747/co.21.1864.

394

Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91. doi:10.1007/s11239-015-1313-4.

395

Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-87. doi:10.3324/haematol.2018.209114.

396

Muñoz Martín AJ, Gallardo Díaz E, García Escobar I. et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22(2):171-86. doi:10.1007/s12094-019-02263-z.

397

Федоткина Ю.А., Панченко Е.П. Тромбозы в онкологии. Часть 2. Атеротромбоз. 2017;(3):3-12.

Fedotkina YuA, Panchenko EP. Thrombosis in oncology. Part 2. Atherothrombosis. 2017;(3):3-12. (In Russ.)

398

Fernandes CJ, Morinaga LTK, Alves JL, et al. Cancer-associated thrombosis: the when, how and why. European Respiratory Review. 2019;28:180119. doi:10.1183/16000617.0119-2018.

399

John AH. Epidemiology of venous thromboembolism. Nat. Rev. Cardiol. 2015;12:464-74. doi:10.1038/nrcardio.2015.83.

400

Alahmari AK, Almalki ZS, Alahmari AK, Guo JJ. Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. Am Health Drug Benefits. 2016;9(4):221-32.

401

Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;4(2):1-51.

Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEO). Phlebology. 2015;4(2):1-51. (In Russ.)

402

Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650. doi:10.1002/14651858.CD006650.pub5.

403

Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566-e581. doi:10.1016/S1470-2045(19)30336-5.

404

Geddings JE, Hisada Y, Boulaftali Y, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14:153-66. doi:10.1111/jth.13181.

405

Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Journal of Clinical Oncology. 2020; 38(5):496-520. doi:10.1200/JCO.19.01461.

406

Navi BB, Reiner AS, Kamel H, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781-9. doi:10.1182/blood-2018-06-860874.

407

Javid M, Magee TR, Galland RB. Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg. 2008;35(1):84-7. doi:10.1016/j.ejvs.2007.08.014.

408

Grilz E, Königsbrügge O, Posch F, et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica. 2018;103(9):1549-56. doi:10.3324/haematol.2018.192419.

409

Mi Y, Yan S, Lu Y, et al. Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine (Baltimore) 2016;95:e4495. doi:10.1097/MD.0000000000004495.

410

Tuzovic M, Herrmann J, Iliescu C, et al. Arterial Thrombosis in Patients with Cancer. Curr. Treat. Options Cardiovasc. Med. 2018;20(5):40. doi:10.1007/s11936-018-0635-x.

411

Rhea IB, Lyon AR, Fradley MG. Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. Curr Oncol Rep. 2019;21(5):45. doi:10.1007/s11912-019-0797-z.

412

Thachil J, Falanga A, Levi M, et al. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13:671-5. doi:10.1111/jth.12838.

413

Алексеева Л.А., Рагимов А.А. ДВС-синдром. 2-е изд., перераб. М.: ГЭОТАР-Медиа. 2020. 96 с. ISBN: 978-5-9704-5797-9.

Alekseeva LA, Ragimov AA. DIC-syndrome. 2nd ed. M.: GEOTAR-Media. 2020. 96 p. (In Russ.) ISBN: 978-5-9704-5797-9.

414

Vitale FV, Longo-Sorbello GS, Rotondo S, Ferrau F. Understanding and treating solid tumorrelated disseminated intravascular coagulation in the “era” of targeted cancer therapies. SAGE Open Med. 2017;5:2050312117749133. doi:10.1177/2050312117749133.

415

Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016;10:649. doi:10.3332/ecancer.2016.649.

416

Wada H, Matsumoto T, Suzuki K, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14. doi:10.1186/s12959-018-0168-2.

417

Кулиева А.А., Емелина Е.И., Гендлин Г.Е. и др. Сердечно-сосудистые осложнения терапии ингибиторами контрольных точек иммунитета. Качественная клиническая практика. 2019;(4):55-65. doi:10.1016/2588-0519-2019-4-55-65.

Kulieva AA, Emelina EI, Gendlin GE, et al. Cardiovascular complications of therapy with immune checkpoint inhibitors. High-quality clinical practice. 2019;(4):55-65. (In Russ.) doi:10.1016/2588-0519-2019-4-55-65.

418

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158-68. doi:10.1056/NEJMra1703481.

419

D’Souza M, Nielsen D, Svane IM, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42:1621-31. doi:10.1093/eurheartj/ehaa884.

420

Esposito R, Fedele T, Orefice S, et al. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. Biomolecules. 2021;11:785. doi:10.3390/biom11060785.

421

Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579-89. doi:10.1016/S1470-2045(18)30608-9.

422

Xu S, Sharma UC, Tuttle C, Pokharel S. Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Front. Cardiovasc. Med. 2021;8:619650. doi:10.3389/fcvm.2021.619650.

423

Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8:e000261. doi:10.1136/jitc-2019-000261.

424

Кушнарева Е.А., Моисеева О.М. Миокардиты, ассоциированные с терапией ингибиторами контрольных точек: систематический анализ клинических случаев. Российский кардиологический журнал. 2020;25(11):3910. doi:10.15829/1560-4071-2020-3910.

Kushnareva E.A., Moiseeva O.M. Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology. 2020;25(11):3910. (In Russ.) doi:10.15829/1560-4071-2020-3910.

425

Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420. doi:10.1016/j.ijcha.2019.100420.

426

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68. doi:10.1200/JCO.2017.77.6385.

427

Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: Contemporary prevalence, management and outcomes. Heart. 2020;106:569-74. doi:10.1136/heartjnl-2019-315852.

428

Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36:2921-64. doi:10.1093/eurheartj/ehv318.

429

Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, et al. Cause and Long-Term Outcome of Cardiac Tamponade. Am J Cardiol. 2016;117:664-9. doi:10.1016/j.amjcard.2015.11.023.

430

Saab J, Hoda RS, Narula N, et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathol. 2017;125:128-37. doi:10.1002/cncy.21790.

431

Patel N, Rafique AM, Eshaghian S, et al. Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol. 2013;112:1235-9. doi:10.1016/j.amjcard.2013.05.066.

432

van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235-43. doi:10.1200/JCO.2015.63.4444.

433

Taylor C, Correa C, Duane FK, et al., Early Breast Cancer Trialists’ Collaborative Group Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35:1641-9. doi:10.1200/JCO.2016.72.0722.

434

Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123-36. doi:10.1016/S1470-2045(14)70409-7.

435

Jacobse JN, Duane FK, Boekel NB, et al. Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys. 2019;103:595-604. doi:10.1016/j.ijrobp.2018.10.025.

436

Rehammar JC, Jensen M-B, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol. 2017;123:299-305. doi:10.1016/j.radonc.2017.03.012.

437

Yavas G, Gultekin M, Yildiz O, et al. Assessment Of concomitant versus equential trastuzumab on radiation-induced cardiovascular toxicity. Hum Exp Toxicol. 2017;36:1121- 30. doi:10.1177/0960327116680276.

438

Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66:337-50. doi:10.3322/caac.21342.

439

Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol 2016;8(9):504-19. doi:10.4330/wjc.v8.i9.504.

440

Sárközy M, Varga Z, Gáspár R. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clinical Research in Cardiology. Clin Res Cardiol. 2021;110(4):507-31. doi:10.1007/s00392-021-01809-y.

441

Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure. 2020;22:1966-83. doi:10.1002/ejhf.2017.

442

Walker V, Lairez O, Fondard O, et al. Myocardial deformation after radiotherapy: a layerspecific and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study). Radiat Oncol. 2020;15(1):201. doi:10.1186/s13014-020-01635-y.

443

van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257-65. doi:10.1182/blood-2016-09-740332.

444

Saiki H, Petersen IA, Scott CG, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;135:1388-96. doi:10.1161/CIRCULATIONAHA.116.025434.

445

Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65:2511-22. doi:10.1016/j.jacc.2015.04.013.

446

Полтавская М.Г., Емелина Е.И., Авдеев Ю.В. и др. Поражения клапанов сердца вследствие лучевой терапии злокачественных новообразований. Кардиология. 2019;59(2S):56-68.

Poltavskaya MG, Emelina EI, Avdeev YuV, et al. Lesions of the heart valves due to radiation therapy of malignant neoplasms. Kardiologija. 2019;59(2S):56-68. (In Russ.)

447

Trivedi SJ, Choudhary P, Lo Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148-54. doi:10.1016/j.radonc.2018.10.023.

448

Plana JC, Thavendiranathan P, Bucciarelli-Ducci C. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. J Am Coll Cardiol Img. 2018;11:1173-86. doi:10.1016/j.jcmg.2018.06.003.

449

Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapyfor breast cancer. N Engl J Med. 2013;368:987-98. doi:10.1056/NEJMoa1209825.

450

Dess RT, Sun Y, Matuszak MM, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35:1395e1402. doi:10.1200/JCO.2016.71.6142.

451

Taylor C, McGale P, Brønnum D, et al. Cardiac structure injury after radiotherapy for breast cancer: cross-sectional study with individual patient data. J Clin Oncol. 2018;36:2288-96. doi:10.1200/JCO.2017.77.6351.

452

Reed GW, Masri A, Griffin BP, et al. Long-term mortality in patients with radiationassociated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016;9:e003483. doi:10.1161/CIRCINTERVENTIONS.115.003483.

453

Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017;187:98-103. doi:10.1016/j.ahj.2017.02.014.

454

Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of valvular disorders in survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy +/- chemotherapy. Am J Cardiol. 2016;117(4):691-6. doi:10.1016/j.amjcard.2015.11.027.

455

van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007-17. doi:10.1001/jamainternmed.2015.1180.

456

Donnellan E, Griffin BP, Johnston DR, et al. Rate of progression of aortic stenosis and its impact on outcomes in patients with radiation-associated cardiac disease: a matched cohort study. J Am Coll Cardiol Img. 2018;11:1072-80. doi:10.1016/j.jcmg.2018.04.019.

457

Donnellan E, Masri A, Johnston DR, et al. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017;6(5):e005396. doi:10.1161/JAHA.116.005396.

458

Desai MY, Cremer PC, Schoenhagen P. Thoracic aortic calcification: diagnostic, prognostic, and management considerations. J Am Coll Cardiol Img. 2018;11:1012-26.

459

Zafar MR, Mustafa SF, Miller TW, et al. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology. 2020;14;6:8. doi:10.1186/s40959-020-00062-y

460

Groarke JD, Tanguturi VK, Hainer J, et al. Abnormal exercise response in long-term survivors of Hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol. 2015;65:573-83. doi:10.1016/j.jacc.2014.11.035.

461

Armanious MA, Mishra S, Fradley MG. Electrophysiologic toxicity of chemoradiation. Curr Oncol Rep. 2018;20:45. doi:10.1007/s11912-018-0691-0.

462

Cardinale D, Colombo A, Sandri MT, et al. Prevention of High-Dose Chemotherapy– Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. Circulation. 2006;114(23):2474-81. doi:10.1161/CIRCULATIONAHA.106.635144.

463

Муратов Р.М., Бабенко С.И., Сачков А.С., Соболева Н.Н. Постлучевое поражение клапанов сердца. Принципы диагностики и результаты лечения. Кардиология. 2019;59(3):36-42. doi:10.18087/cardio.2019.3.10239.

Muratov RM, Babenko SI, Sachkov AS, Soboleva NN. Post-radiation damage of heart valves. Principles of diagnosis and treatment results. Kardiologija. 2019;59(3):36-42. (In Russ.) doi:10.18087/cardio.2019.3.10239.

464

Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. department of health and human services, National Institutes of Health, National Cancer Institute. Publish Date: November 27, 2017. For further details on MedDRA refer to the MedDRA MSSO Web site (https://www.meddra.org/).

465

Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. BMJ. 2018; 104(12):971-7. doi:10.1136/heartjnl-2017-312103.

466

Buza V, Rajagopalan B, Curtis AB. Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 2017;10(8):e005443. doi:10.1161/CIRCEP.117.005443.

467

Rhea PH, Burgos MG. Fradley. Arrhythmogenic Anticancer Drugs in Cardio-Oncology. Cardiol Clin. 2019;37:459-68. doi:10.1016/j.ccl.2019.07.011.

468

Емелина Е.И., Гендлин Г.Е., Никитин И.Г., и др. Нарушения ритма и проводимости у пациентов, получающих лечение ибрутинибом. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2019;12(2):220-30. doi:10.21320/2500-2139-2019-12-2-220-230.

Emelina EI, Gendlin GE, Nikitin IG, et al. Rhythm and conduction disorders in patients receiving treatment with ibrutinib. Clinical oncohematology. Basic research and clinical practice. 2019;12(2):220-30. (In Russ.) doi:10.21320/2500-2139-2019-12-2-220-230.

469

Емелина Е. И., Гендлин Г.Е., Никитин И. Г. Антитромботическая терапия у пациентов со злокачественными лимфопролиферативными заболеваниями, получающих ибрутиниб. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2019;12(4):89-100. doi:10.21320/2500-2139-2019-12-4-449-460.

Emelina EI, Gendlin GE, Nikitin IG. Antithrombotic therapy in patients with malignant lymphoproliferative diseases receiving ibrutinib. Clinical oncohematology. Basic research and clinical practice. 2019;12(4):89-100. (In Russ.) doi:10.21320/2500-2139-2019-12-4-449-460.

470

Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.

Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.

471

Gregorietti V, Fernandez TL, Costa D, et al. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6(1):24. doi:10.1186/s40959-020-00078-4.

472

Singh JP, Solomon SD, Fradley MG, et al. Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With ChemotherapyInduced Cardiomyopathy. JAMA. 2019;322(18):1799-805. doi:10.1001/jama.2019.16658.

473

Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-12. doi:10.1016/j.amjcard.2012.10.048.

474

Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139 (21):997-1012. doi:10.1161/CIR.0000000000000679.

475

Maia TN, Araujo GB, Teixeira JA, et al. Cardiotoxicity of Doxorubicin Treatment and Physical Activity: A Systematic Review. Int J Cardiovasc Sci. 2017;30(1):70-80. doi:10.5935/2359-4802.20170004.

476

Fischetti F, Greco G, Cataldi S, et al. Effects of Physical Exercise Intervention on Psychological and Physical Fitness in Lymphoma Patients. Medicina 2019;55(7):379. doi:10.3390/medicina55070379.

477

Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365-75. doi:10.1093/jnci/djk064.

478

Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med.2011;155:21-32. doi:10.7326/0003-4819-155-1-201107050-00004.

479

Бойцов С.А., Погосова Н.В., Бубнова М.Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.

Boytsov SA, Pogosova NV, Bubnova MG, et al. Cardiovascular prevention 2017. Russian national recommendations. Russian Journal of Cardiology. 2018;23(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.

480

Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2014;2014(12):CD011273. doi:10.1002/14651858.CD011273.pub2.

481

Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/ secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007;115:2675- 82. doi:10.1161/CIRCULATIONAHA.106.180945.

482

Hamm LF, Sanderson BK, Ades PA, et al. Core competencies for cardiac rehabilitation/ secondary prevention professionals: 2010 update: position statement of the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev. 2011;31:2-10. doi:10.1097/HCR.0b013e318203999d.

483

Бокерия Л. А., Аронов Д. М. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика. КардиоСоматика. 2016;7(3-4):5-71.

Bokeria LA, Aronov DM. Russian clinical guidelines. Coronary bypass surgery in patients with coronary heart disease: rehabilitation and secondary prevention. Cardiosomatics. 2016;7(3-4):5-71. (In Russ.)

484

Арутюнов Г.П., Беграмбекова Ю.Л., Васюк Ю.А. и др. Рекомендации по назначению физических тренировок пациентам с хронической сердечной недостаточностью. Сердечная недостаточность. 2017;18(1):41-66.

Arutyunov GP, Begrambekova YuL, Vasyuk YuA, et al. Recommendations for the appointment of physical training in patients with chronic heart failure. Heart failure. 2017;18(1):41-66. (In Russ.)

485

Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi:10.15829/29/1560-4071-2020-4103.

Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/29/1560-4071-2020-4103.

486

Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) European Heart Journal. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.

487

Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-56. doi:10.1016/j.healun.2010.05.034.

488

Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J PrevCardiol. 2014;21(6):664-81. doi:10.1177/2047487312449597.

489

Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30:2530-7. doi:10.1200/JCO.2011.39.9014.

490

Peel AB, Barlow CE, Leonard D, et al. Cardiorespiratory fitness in survivors of cervical, endometrial, and ovarian cancers: the Cooper Center Longitudinal Study. Gynecol Oncol. 2015;138:394-7. doi:10.1016/j.ygyno.2015.05.027.

491

Peel AB, Thomas SM, Dittus K, et al. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc. 2014;3:e000432. doi:10.1161/JAHA.113.000432.

492

Miller AM, Lopez-Mitnik G, Somarriba G, et al. Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Blood Cancer. 2013;60:663-8. doi:10.1002/pbc.24410.

493

De Caro E, Smeraldi A, Trocchio G, et al. Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. Pediatr Blood Cancer. 2011;56:122-6. doi:10.1002/pbc.22606.

494

Mason С, Alfano СM, Smith AW, et al. Long-term physical activity trends in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1153-61. doi:10.1158/1055-9965.EPI-13-0141.

495

Stevinson C, Lydon A, Amir Z. Adherence to physical activity guidelines among cancer support group participants. Eur J Cancer Care (Engl). 2014;23(2):199-205. doi:10.1111/ecc.12145.

496

Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 2009;27:4605-12. doi:10.1200/JCO.2008.20.0634.

497

Lakoski SG, Willis BL, Barlow CE, et al. Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men: the Cooper Center Longitudinal Study. JAMA Oncol. 2015;1:231-7. doi:10.1001/jamaoncol.2015.0226.

498

Okwuosa TM, Ray RM, Palomo A, et al. Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast Cancer: Women’s Health Initiative. J Am Coll Cardiol Cardio Onc. 2019;1(1):41-50. doi:10.1016/j.jaccao.2019.08.014.

499

Anderson L, Oldridge N, Thompson DR, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016;67(1):1-12. doi:10.1016/j.jacc.2015.10.044.

500

Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328(7433):189. doi:10.1136/bmj.37938.645220.EE.

501

Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176-91. doi:10.1161/CIRCULATIONAHA.117.024671.

502

Scott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297-305. doi:10.1200/JCO.2017.77.5809.

503

Dittus KL, Lakoski SG, Savage PD, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J Cardiopulm Rehabil Prev. 2015;35:130-9. doi:10.1097/HCR.0000000000000091.

504

Schmidt ME, Wiskemann J, Armbrust P, et al. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer. 2015;137(2):471-80. doi:10.1002/ijc.29383.

505

Qiang W, Dong F, Yan L, et al. Rehabilitation effect of systematic exercise on breast cancer patients after adjuvant chemotherapy. Clin. Oncol. Cancer Res. 2010;7:259-64. doi:10.1007/s11805-010-0528-6.

506

Lipsetta A, Barretta S, Harunaa F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and metaanalysis. The Breast. 2017;32:144-55. doi:10.1016/j.breast.2017.02.002.

507

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1(1):CD011292. doi:10.1002/14651858.CD011292.pub2.

508

Jones LW, Liu Q, Armstrong GT, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:3643–50. doi:10.1200/JCO.2014.56.7511.

509

Jones LW, Habel LA, Weltzien E, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 2016;34:2743-9. doi:10.1200/JCO.2015.65.6603.

510

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies, Acta Oncologica. 2015;54(5):635-54. doi:10.3109/0284186X.2014.998275.

511

Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25(7):1293-311. doi:10.1093/annonc/mdu012.

512

Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104-14. doi:10.1161/CIRCULATIONAHA.115.020406.

513

Campia U, Moslehi JJ, Amiri-Kordestani A, et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation. 2019;139(13):e579-e602. doi:10.1161/CIR.0000000000000641.

514

Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597-605. doi:10.1200/JCO.2005.02.5841.

515

Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231- 8. doi:10.1200/JCO.2007.13.5467.

516

Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34:1122-30. doi:10.1200/JCO.2015.64.0409.

517

Jefford M, Rowland J, Grunfeld E, et al. Implementing improved post-treatment care for cancer survivors in England, with reflections from Australia, Canada and the USA. Br J Cancer. 2013;108:14-20. doi:10.1038/bjc.2012.554.

518

Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361:664-73. doi:10.1056/NEJMoa0810118.

519

Ehrman JK, Liguori G, Magal M, Riebe D. ACSM’s Guidelines for Graded Exercise Testing and Prescription. American College of Sports Medicine. 10th ed. Philadelphia: Wolters Kluwer. 2018:423-36.

520

Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographicassessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973;85:546-62.

521

Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. U S Armed Forces Med J. 1959;10:675-88.

522

Naughton J, Balke B, Nagle F. Refinements in Method of Evaluation and Physical Conditioning Before and After Myocardial Infarction. Am J Cardiol.1964;14:837-43.

523

Lakoski SG, Barlow CE, Koelwyn GJ, et al. The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study. Breast Cancer Res Treat. 2013;138:909-16. doi:10.1007/s10549-013-2478-1.

524

Schmidt K, Vogt L, Thiel C, et al. Validity of the six-minute walk test in cancer patients. Int J Sports Med. 2013;34:631-6. doi:10.1055/s-0032-1323746.

525

Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association.Circulation. 2001;104:1694-740. doi:10.1161/hc3901.095960.

526

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7. doi:10.1164/ajrccm.166.1.at1102.

527

Swedish National Institute of Public Health. Physical activity in the prevention and treatment of disease.2010.

Swedish National Institute of Public Health. Physical activity in the prevention and treatment of disease. 2010.

528

Prado СМ, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. Journal of Cachexia, Sarcopenia and Muscle. 2020;11:366-80. doi:10.1002/jcsm.12525.

529

Maitland ML, Bakris GL, Black HR, et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growthfactor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604. doi:10.1093/jnci/djq091.

530

Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Часть II-V. Системные гипертензии. 2017;14(4):6-19. doi:10.26442/2075-082X_14.4.6-19.

Chazova IE, Tyulyandin SA, Vitsenya MV, et al. Guidelines for the diagnosis, prevention and treatment of cardiovascular complications of antitumor therapy. Part II-V. Systemic hypertension. 2017;14(4):6-19. (In Russ.) doi:10.26442/2075-082X_14.4.6-19.

531

Кухарчук В.В., Ежов М.В., Сергиенко И.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.

Kukharchuk VV, Yezhov MV, Sergienko IV, etc. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.

532

Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206- 14. doi:10.1093/jnci/djk029.

533

CCSS | CCSS Cardiovascular Risk Calculator (stjude.org)

534

https://rae-org.ru/system/files/documents/pdf/saharnyy_diabet_2_tipa_u_vzroslyh.pdf

535

Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181:1998-2006. doi:10.1016/j.juro.2009.01.047.

536

Meacham LR, Sklar CA, Li S, Liu Q, et al. Diabetes mellitus in long-term survivors of childhood cancer: increased risk associated with radiation therapy: a report for the Childhood Cancer Survivor Study. Arch Intern Med. 2009;169:1381-8. doi:10.1001/archinternmed.2009.209.

537

Squires RW, Kaminsky LA, Porcari JP, et al. Progression of exercise training in early outpatient cardiac rehabilitation: An Official Statement From The American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev. 2018;38:139- 46. doi:10.1097/HCR.0000000000000337.

538

D’Ascenzi F, Anselmi F, Fiorentini C, et al. The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. European Journal of Preventive Cardiology. 2019;2047487319874900. doi:10.1177/2047487319874900.

539

Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.

540

Lakoski SG, Jones LW, Krone RJ, et al. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. Am Heart J. 2015;170:231- 41. doi:10.1016/j.ahj.2015.05.014.

541

Dolan LB, Campbell K, Gelmon K, et al. Interval versus continuous aerobic exercise training in breast cancer survivors a pilot RCT. Support Care Cancer. 2016;24:119-27. doi:10.1007/s00520-015-2749-y.

542

Toohey K, Pumpa KL, Arnolda L, et al. A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. Peer J. 2016;4:e2613. doi:10.7717/peerj.2613.

543

Molassiotis A, Charalambous A, Taylor P, et al. The effect of resistance inspiratory muscle training in the management of breathlessness in patients with thoracic malignancies: A feasibility randomised trial. Support Care Cancer. 2015;23:1637-45. doi:10.1007/s00520-014-2511-x.

544

Jolly K, Taylor RS, Lip GYH, Stevens A. Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care: a systematic review and meta-analysis. Int J Cardiol. 2006;111(3):343-51. doi:10.1016/j.ijcard.2005.11.002.

545

Тaylor R, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2010;1:CD007130. doi:10.1002/14651858.CD007130.pub2.

546

Dalal HM, Zawada A, Jolly K, et al. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ. 2010;340:b5631. doi:10.1136/bmj.b5631.

547

Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2017;6(6):CD007130. doi:10.1002/14651858.CD007130.pub4.

548

Avila A, Claes J, Buys R, et al. Home-based exercise with telemonitoring guidance in patients with coronary artery disease: Does it improve long-term physical fitness? Eur J Prev Cardiol. 2020;27: 367-77. doi:10.1177/2047487319892201.

549

Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapyinduced cardiotoxicity: What is missing? Pharmacol Ther. 2016;168:113-25. doi:10.1016/j.pharmthera.2016.09.009.

550

Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683-95.

551

Christidi E, Huang H, Shafaattalab S, et al. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cellderived cardiomyocytes. Scientific reports. 2020;10(1):10363. doi:10.1038/s41598-020-65979-x.

552

Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. Journal of the American College of Cardiology. 2018;71(20):2293-302. doi:10.1016/j.jacc.2018.03.462.

553

Linschoten M, Teske AJ, Baas AF, et al. Truncating Titin (TTN) Variants in ChemotherapyInduced Cardiomyopathy. Journal of cardiac failure. 2017;23(6):476-9.

554

Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019;140(1):31-41. doi:10.1161/CIRCULATIONAHA.118.037934.

555

Wang X, Sun C-L, Quiñones-Lombraña A, et al. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study. Journal of Clinical Oncology. 2016;34(8):863-70. doi:10.1200/JCO.2015.63.4550.

556

Serie DJ, Crook JE, Necela BM, et al. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017;27(10):378-85. doi: 10.1097/FPC.0000000000000302.

557

Serie DJ, Crook JE, Necela BM, et al. Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy. J Cardiovasc Dev Dis. 2017;4(2):6. doi:10.3390/jcdd4020006.

558

Niemeijer MN, Van Den Berg ME, Eijgelsheim M, et al. Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update. Drug Safety. 2015;38(10):855-67. doi:10.1007/s40264-015-0316-6.

559

Adler A, Novelli V, Amin AS, et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation. 2020;141(6):418-28. doi:10.1161/CIRCULATIONAHA.119.043132.

The authors declare that there are no conflicts of interest present.